University Professor and Co-director, Center for Applied Proteomics and Molecular Medicine
A renowned proteomics and cell signaling expert, Petricoin came to George Mason University from the U.S. Food and Drug Administration Center for Biologics Evaluation and Research, where he served as a senior investigator. His expertise also includes drug and biologic effects on signal transduction and kinase-driven cascades, diagnostic platform development, pathogenic microbiology, and artificial intelligence-based bioinformatics tools.
Petricoin holds a doctorate in microbiology from the University of Maryland at College Park. He serves on numerous editorial boards, has co-written more than 170 articles for peer-reviewed publications, and is a member of the American Association for Cancer Research.
Petricoin and Center for Applied Proteomics and Molecular Medicine Co-director Lance A. Liotta, who are internationally recognized for their pioneering research in proteomics and molecular medicine, co-founded the George Mason University Center for Applied Proteomics and Molecular Medicine in 2005. They currently are exploring their recent discovery of an archive of protein fragments in the blood that are biomarker candidates for breast, ovarian, and lung cancers. Their immediate goals are to validate these potential biomarkers in clinical trials to determine their feasibility in the diagnosis of cancer prior to metastasis, and to analyze molecular pathways in diseased tissue to determine individualized and targeted treatments for patients. The team also is investigating the development and use of nanotechnology to synergize with proteomic tools for new types of biosensors, nanoparticles for biomarker discovery, and nanoelectronics. Liotta and Petricoin have more than 20 patents pending in the areas of cancer theranostics, biomarkers, and related technologies.
Media Contact: Michele McDonald, 703-993-8781, email@example.com